Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

Long-Term VIVID-2 Data for Mirikizumab in Crohn’s Disease, with Edward Barnes, MD, MPH

Findings from the VIVID-2 open-label extension study in patients with CD highlight long-term clinical and endoscopic outcomes with mirikizumab.

VIVID-2: Mirikizumab (Omvoh) Shows Long-Term Efficacy for Crohn’s Disease

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Gastroenterology Month in Review: January 2025

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.

MASLD, MetALD Cardiometabolic Risk Factors Linked to Increased Long-Term Risk of IBD

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

Marla Dubinsky, MD: Ushering In a New Era of Crohn’s Disease Treatment with Mirikizumab

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

FDA Approves Mirikizumab (Omvoh) for Crohn’s Disease

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

Duvakitug Meets Primary Endpoints in Phase 2b RELIEVE UCCD Study for IBD

The supplemental Biologics License Application is supported by the phase 3 ASTRO study of guselkumab SC induction therapy in ulcerative colitis.

J&J Submits sBLA for Guselkumab (Tremfya) Subcutaneous Induction Regimen in UC

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

Children with IBD Respond Well to the Pfizer COVID-19 Vaccination, with Arthur Kastl, MD

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

Laura Hamant, MD: Standardized Algorithm Increases VTE Prophylaxis Among Children

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Inflammatory Bowel Disease